Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
Figure 12
Roles of the carbamate moiety in drugs and prodrugs
| Drug | The role of the carbamate moiety in the drug | Reference |
|---|---|---|
| Docetaxel | prolongs drug action, increases drug potency, improves water solubility | 39 |
| Mytomicin C | participates in the formation of an alkylating compound during reaction with target | 40 |
| Rivastigmine, neostigmine, physostigmine, pyridostigmine | key element for interaction with the target | 38 |
| Ritonavir, amprenavir, atazanavir, darunavir | improves drug bioavailability and potency, engaged in a backbone interaction with protease | 8 |
| Ombitasvir, elbasvir, daclatasavir | improves drug stability and lipophilicity | 41 |
| Febendazole, mebendazole, febantel, albendazole | improves aqueous solubility and bioavailability, increases cytotoxicity | 42 |
| Mehocarabamol, metaxalone | inhibits acetylcholinesterase at synapses in the autonomic nervous system, neuromuscular junction, and central nervous system | 43 |
| Felbamate | improves drug stability and bioavailability | 44, 45 |
| Retigabine | major pharmacophore responsible for interacting with residues in the KCNQ2–5 channels | 46 |
| Gabapentin enacarbil | improves bioavailability | 47 |
| Capecitabine | improves selectivity and bioavailability | 47 |
| Bambuterol | delays first-pass metabolism | 47 |
| Irinotecan | improves aqueous solubility | 47 |